ranolazine
- Product NDC
- 69844-025
- 11-digit product format
- 698440025
- Labeler code
- 69844
- Product ID
- 69844-025_ef140e7b-b519-b66d-e053-2a95a90a2305
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- extended-release
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Graviti Pharmaceuticals Private Limited
- Application
- ANDA212889
- Marketing category
- ANDA
- Marketing start
- 2021-01-28
- Marketing end
- 0000-00-00
- Substance
- RANOLAZINE
- Active strength
- 1000 mg/1
- Pharmacologic classes
- Anti-anginal [EPC], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Organic Cation Transporter 2 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 69844-025-01 | 69844002501 | 30 TABLET in 1 BOTTLE (69844-025-01) | 30 tablet | 2021-01-28 | 0000-00-00 | No | No | Current |
| 69844-025-02 | 69844002502 | 60 TABLET in 1 BOTTLE (69844-025-02) | 60 tablet | 2021-01-28 | 0000-00-00 | No | No | Current |
| 69844-025-03 | 69844002503 | 500 TABLET in 1 BOTTLE (69844-025-03) | 500 tablet | 2021-01-28 | 0000-00-00 | No | No | Current |